Company: U.S Food and Drug Administration (FDA)
Job title: Senior Advisor for Toxicology Center for Food Safety and Applied Nutrition
Dr. Suzanne Fitzpatrick is the Senior Advisor for Toxicology in the Office of the Center Director at Center for Food Safety and Applied Nutrition at the US Food and Drug Administration. Dr. Fitzpatrick is a board-certified toxicologist in the US and in Europe. Dr. Fitzpatrick is also an Adjunct Professor at Johns Hopkins University. Dr. Fitzpatrick received her BA from the University of California at San Diego and her PhD from Georgetown University. Dr. Fitzpatrick was the FDA lead for the FDA NIH Common Fund award to Wyss Institute to develop a heart lung micromachine. She then helped develop the FDA DARPA NCATS program on Organs on a Chip and continues to work and give presentations on this evolving area. She developed a research agreement with Emulate to bring the first organ on a chip model into an Dr. Fitzpatrick is the FDA lead for Tox 21 and is the FDA Principal Representative to ICCVAM. She chaired the FDA Predictive Toxicology RoadMap Committee and is on the FDA Leadership Council for the FDA Roadmap Implementation Committee. She is on the EU Tox Risk Regulator Committee. Dr. Fitzpatrick has received several awardsincluding the 2019 SOT Enhancement of Animal Welfare Award. Dr. Fitzpatrick served on the planning committees for SOT Future Tox I, II, and III, and the co-chair of Future Tox IV. She is a Past President of the American College of Toxicology. Currently she is the Secretary Elect on the Society of Toxicology Council. Dr. Fitzpatrick believes strongly in working with together with all stakeholders both nationally and internationally to develop new alternative methods for regulatory testing.
Live Q&A – Ask the Speakers Your Burning Questions 10:10 am
day: Day Two
FDA Insight: Utilizing 3D Models to Drive Drug Development & Regulatory Acceptance 9:10 am
Outlining the latest developments to incorporate 3D model data to support translational success Addressing the evidence required to advance drug candidates from preclinical 3D studies into phase I clinical trials The need to adapt guidelines, define context of use across the model continuum and using 3D systems to support in vivo evidenceRead more
day: Day Two